These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 26168096)

  • 1. LLNA variability: An essential ingredient for a comprehensive assessment of non-animal skin sensitization test methods and strategies.
    Hoffmann S
    ALTEX; 2015; 32(4):379-83. PubMed ID: 26168096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of vehicle on the relative potency of skin-sensitizing chemicals in the local lymph node assay.
    Jowsey IR; Clapp CJ; Safford B; Gibbons BT; Basketter DA
    Cutan Ocul Toxicol; 2008; 27(2):67-75. PubMed ID: 18568891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin sensitization testing in potency and risk assessment.
    Kimber I; Basketter DA; Berthold K; Butler M; Garrigue JL; Lea L; Newsome C; Roggeband R; Steiling W; Stropp G; Waterman S; Wiemann C
    Toxicol Sci; 2001 Feb; 59(2):198-208. PubMed ID: 11158712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local lymph node assay (LLNA) for detection of sensitization capacity of chemicals.
    Gerberick GF; Ryan CA; Dearman RJ; Kimber I
    Methods; 2007 Jan; 41(1):54-60. PubMed ID: 16938465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative relationship between the local lymph node assay and human skin sensitization assays.
    Schneider K; Akkan Z
    Regul Toxicol Pharmacol; 2004 Jun; 39(3):245-55. PubMed ID: 15135206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of BALB/c mouse in the local lymph node assay:BrdU-ELISA for the prediction of the skin sensitizing potential of chemicals.
    Hou F; Xing C; Li B; Cheng J; Chen W; Zhang M
    J Pharmacol Toxicol Methods; 2015; 72():53-8. PubMed ID: 25600862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nothing is perfect, not even the local lymph node assay: a commentary and the implications for REACH.
    Basketter DA; McFadden JF; Gerberick F; Cockshott A; Kimber I
    Contact Dermatitis; 2009 Feb; 60(2):65-9. PubMed ID: 19207375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive identification of human skin sensitization thresholds.
    Basketter DA; Clapp C; Jefferies D; Safford B; Ryan CA; Gerberick F; Dearman RJ; Kimber I
    Contact Dermatitis; 2005 Nov; 53(5):260-7. PubMed ID: 16283904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical applicability domain of the Local Lymph Node Assay (LLNA) for skin sensitisation potency. Part 2. The biological variability of the murine Local Lymph Node Assay (LLNA) for skin sensitisation.
    Roberts DW; Api AM; Aptula AO
    Regul Toxicol Pharmacol; 2016 Oct; 80():255-9. PubMed ID: 27470439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel approach for classifying chemicals according to skin sensitizing potency by non-radioisotopic modification of the local lymph node assay.
    Takeyoshi M; Iida K; Shiraishi K; Hoshuyama S
    J Appl Toxicol; 2005; 25(2):129-34. PubMed ID: 15744759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The local lymph node assay: past, present and future.
    Kimber I; Dearman RJ; Basketter DA; Ryan CA; Gerberick GF
    Contact Dermatitis; 2002 Dec; 47(6):315-28. PubMed ID: 12581276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-enzymatic glutathione reactivity and in vitro toxicity: a non-animal approach to skin sensitization.
    Aptula AO; Patlewicz G; Roberts DW; Schultz TW
    Toxicol In Vitro; 2006 Mar; 20(2):239-47. PubMed ID: 16112535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contact allergenic potency: correlation of human and local lymph node assay data.
    Gerberick GF; Robinson MK; Ryan CA; Dearman RJ; Kimber I; Basketter DA; Wright Z; Marks JG
    Am J Contact Dermat; 2001 Sep; 12(3):156-61. PubMed ID: 11526521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The local lymph node assay and the assessment of relative potency: status of validation.
    Basketter DA; Gerberick F; Kimber I
    Contact Dermatitis; 2007 Aug; 57(2):70-5. PubMed ID: 17627643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of human contact allergens in the murine local lymph node assay.
    Ryan CA; Gerberick GF; Cruse LW; Basketter DA; Lea L; Blaikie L; Dearman RJ; Warbrick EV; Kimber I
    Contact Dermatitis; 2000 Aug; 43(2):95-102. PubMed ID: 10945748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating skin sensitization potency from a single dose LLNA.
    Roberts DW
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):437-43. PubMed ID: 25625585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of skin sensitization potency using machine learning approaches.
    Zang Q; Paris M; Lehmann DM; Bell S; Kleinstreuer N; Allen D; Matheson J; Jacobs A; Casey W; Strickland J
    J Appl Toxicol; 2017 Jul; 37(7):792-805. PubMed ID: 28074598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A chemical dataset for evaluation of alternative approaches to skin-sensitization testing.
    Gerberick GF; Ryan CA; Kern PS; Dearman RJ; Kimber I; Patlewicz GY; Basketter DA
    Contact Dermatitis; 2004 May; 50(5):274-88. PubMed ID: 15209809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An in vitro human skin test for assessing sensitization potential.
    Ahmed SS; Wang XN; Fielding M; Kerry A; Dickinson I; Munuswamy R; Kimber I; Dickinson AM
    J Appl Toxicol; 2016 May; 36(5):669-84. PubMed ID: 26251951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the local lymph node assay in the evaluation of the sensitizing potential of pharmaceutical process intermediates.
    Durand G; de Burlet G; Virat M; Nauman BD
    Contact Dermatitis; 2003 Sep; 49(3):148-54. PubMed ID: 14678211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.